Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Moderna begins study on variant-specific COVID-19 vaccine

By Brian Buntz | April 5, 2021

Moderna

Moderna Logo (PRNewsFoto/Moderna Therapeutics)

Moderna (NSDQ:MRNA) is beginning a new Phase 1 study to test the effectiveness of a new version of its COVID-19 vaccine designed to enhance protection against the B.1.351 first detected in South Africa. 

The recent study will help Moderna and its partner, the National Institute of Allergy and Infectious Diseases determine whether to update the vaccine. 

Moderna had announced its plans to launch the study in January. 

In February, the company announced that it had completed manufacturing of a variant-specific vaccine candidate, known as 1273.351. Moderna anticipates that the clinical trial will be fully enrolled by the end of April. 

The B.1.351 variant has similar mutations to other variants of concern spotted in the U.K. and Brazil. 

The study will enroll approximately 210 healthy adults in four centers across the U.S. 

Moderna is also testing using booster doses of its existing vaccine to boost neutralizing immunity against B.1.351 and other variants of concern.

The company will also test a multivalent booster candidate known as mRNA-1273.211 that combines its original vaccine with the mRNA-1273.351 version. 

Researchers have identified the B. 1.351 SARS-CoV-2 variant in nine U.S. states. 

The B.1.351 variant can evade vaccine-induced immunity to some extent. Although vaccines from Pfizer and BioNTech, and Moderna remain largely effective at neutralizing the variant, the AstraZeneca vaccine is less so. A study published in NEJM found it 10.4% effective at protecting against mild-to-moderate COVID-19 infections linked to the B. 1.351 variant. 

In in vitro experiments, Moderna found the variant led to a sixfold reduction in neutralizing antibodies that its vaccine generates against the B. 1.351 SARS-CoV-2 variant compared to earlier strains.

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Johnson & Johnson
Feds halt J&J COVID-19 vaccine due to blood clot concern
Pfizer-BioNTech
Pfizer asks FDA to authorize its COVID-19 vaccine for younger teens
Johnson & Johnson
EMA begins investigation of J&J COVID-19 vaccine’s blood clotting potential 
mouse
When can computer models replace animal trials?

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards